Factors affecting rise in the incidence of infiltrating lobular carcinoma of the breast

Israel Medical Association Journal

Volumn 12, Issue 11, 2010, Pages 697-700

  Chikman, Bar ^a   Lavy, Ron ^a   Davidson, Tima ^b,c   Wassermann, Ilan ^a   Sandbank, Judith ^a,b   Siegelmann Danieli, Nava ^d   Halevy, Ariel ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d Maccabi Health Organization   (Israel)

Author keywords

Breast cancer; Hormone replacement therapy; In vitro fertilization; Lobular carcinoma of the breast

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER INFILTRATION; CANCER INVASION; COHORT ANALYSIS; FEMALE; FERTILIZATION IN VITRO; HORMONE SUBSTITUTION; HUMAN; INFILTRATING LOBULAR CARCINOMA OF THE BREAST; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MIXED TUMOR; OVARY HYPERSTIMULATION; TREND STUDY;

AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; FEMALE; FERTILIZATION IN VITRO; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; ISRAEL; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78650072847     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003; 289: 1421-4.
2. Verkooijen HM, Fioretta G, Vlastos G, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003; 107: 778-81.
3. Henson D, Tarone RA. A study of lobular carcinoma of the breast based on the Third National Cancer Survey in the United States of America. Tumori 1979; 65: 133-42.
4. Ashikari R, Huvos AG, Urban JA, Robbins GF. Infiltrating lobular carcinoma of the breast. Cancer 1973; 31: 110-16.
5. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545-5.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
7. Thom MH, White PJ, Williams RM, et al. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 1979; 2: 455-7.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.
9. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254-63.
10. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 2007; 14: 549-67.
11. Silverman BG, Kokia ES. Use of hormone replacement therapy, 1998- 2007: sustained impact of the Women's Health Initiative findings. Ann Pharmacother 2009; 43: 251-8.
12. Zhao H, Langerød A, Ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004; 15: 2523-36.
13. Günther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schröder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001; 193: 40-7.
14. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004; 6: R149-56.
15. Keinan-Boker L, Lerner-Geva L, Kaufman B, Meirow D. Pregnancy associated breast cancer. IMAJ Isr Med Assoc J 2008; 10: 722-7.
16. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilization. Lancet 1999; 354: 1573-4.
17. Brinton LA, Scoccia B, Moghissi KS, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004; 19: 2005-13.
18. Pappo I, Lerner-Geva L, Halevy A, et al. The possible association between IVF and breast cancer. Ann Surg Oncol 2008; 15: 1048-55.
19. Evans WP, Burhenne LJ, Laurie L, O'Shaughnessy KF, Castellino RA. Invasive lobular carcinoma of the breast: mammographic characteristics and computer-aided detection. Radiology 2002; 225: 182-9.
20. Lopez JK, Bassett LW. Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. Radiographics 2009; 29:165-76.
21. Selinko VL, Middleton LP, Dempsey PJ. Role of sonography in diagnosing and staging invasive lobular carcinoma. J Clin Ultrasound 2004; 32: 323-32.
22. Weinstein SP, Orel SG, Heller R, et al. MR imaging of the breast in patients with invasive lobular carcinoma. AJR Am J Roentgenol 2001; 176: 399-406.
23. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 2000; 24: 1650-6.
24. Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005; 207: 1-13.
25. Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base. Ann Surg 2005; 242: 281-9.